JRCT ID: jRCT2080224968
Registered date:29/11/2019
Basic Information
Recruitment status | recruiting |
---|---|
Health condition(s) or Problem(s) studied | |
Date of first enrollment | 08/06/2020 |
Target sample size | 412 |
Countries of recruitment | Japan,North America,South America,Europe,Oceania |
Study type | Interventional |
Intervention(s) | investigational material(s) Generic name etc : INN of investigational material : cemiplimab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material : control material(s) Generic name etc : INN of investigational material : - Therapeutic category code : --- Other Dosage and Administration for Investigational material : |
Outcome(s)
Primary Outcome | efficacy |
---|---|
Secondary Outcome | efficacy efficacy efficacy efficacy safety safety safety pharmacokinetics other |
Key inclusion & exclusion criteria
Age minimum | >= 21age old |
---|---|
Age maximum | Not applicable |
Gender | Both |
Include criteria | |
Exclude criteria |
Related Information
Primary Sponsor | |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) | NCT03969004,2019-000566-38,JapicCTI-195056 |
Contact
Public contact | |
Name | |
Address | |
Telephone | +81-3-6301-3670 |
clinical-trials-jp@sanofi.com | |
Affiliation | |
Scientific contact | |
Name | |
Address | |
Telephone | +81-3-6301-3670 |
clinical-trials-jp@sanofi.com | |
Affiliation |